Gross Margin: A company's total sales revenue minus its cost of goods sold, divided by the total sales revenue, expressed as a percentage. Calculated as: Gross Income / Total Revenues
Alnylam Pharmaceuticals, Inc. (ALNY) had Gross Margin of 75.60% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$1.10B |
|
$186.42M |
|
$267.72M |
|
$829.31M |
|
$965.31M |
|
$131.72M |
|
$29.42M |
|
$161.14M |
|
$161.14M |
|
$186.42M |
|
$186.42M |
|
$186.42M |
|
$186.42M |
|
$131.72M |
|
$145.22M |
|
131.00M |
|
134.68M |
|
$1.43 |
|
$1.44 |
|
| Balance Sheet Financials | |
$4.05B |
|
$513.15M |
|
$915.67M |
|
$4.97B |
|
$1.47B |
|
$1.01B |
|
$2.71B |
|
$4.18B |
|
$789.18M |
|
$789.18M |
|
$789.18M |
|
132.38M |
|
| Cash Flow Statement Financials | |
$524.08M |
|
$436.33M |
|
$-305.19M |
|
$968.65M |
|
$1.66B |
|
$690.15M |
|
$348.24M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.76 |
|
-- |
|
-- |
|
0.56 |
|
1.28 |
|
|
Gross Margin |
75.60% |
12.01% |
|
12.01% |
|
-- |
|
14.69% |
|
16.99% |
|
$465.38M |
|
-- |
|
-- |
|
-- |
|
0.22 |
|
3.24 |
|
1.41 |
|
63.79 |
|
23.62% |
|
23.62% |
|
3.75% |
|
10.37% |
|
$5.96 |
|
$3.46 |
|
$3.89 |
|